Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: February 25, 2025
Event Date: February 25, 2025 (Agreement); February 26, 2025 (Closing)
Context: The Company entered into a Warrant Inducement Agreement with holders of existing warrants issued in private placements in August and October 2024. The transaction involved the immediate cash exercise of existing warrants at a reduced price in exchange for the issuance of new warrants.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $1.4 million received from the exercise of existing warrants.
- Existing Warrants Exercised:
- October Warrants: Up to 1,302,082 shares.
- August Warrants: Up to 1,136,391 shares.
- Total Existing Warrant Shares: 2,438,473 shares.
- Reduced Exercise Price (Existing): $0.58 per share.
- New Warrants Issued: 2,926,166 shares (120% of existing warrant shares).
- New Warrant Exercise Price: $0.85 per share.
- Financial Advisor Fees:
- Cash Fee: 8.0% of aggregate gross proceeds.
- Expense Reimbursement: Up to $55,000.
- Advisor Warrants: 87,785 shares (approx. 3.0% of new warrant shares) at $0.85 exercise price.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Transaction Structure
The primary material change is the modification of rights for existing warrant holders and the dilution of current shareholders through the issuance of new equity instruments.
- Price Reduction: Existing warrant holders exercised at $0.58/share, a reduction from their original terms, in exchange for immediate cash exercise.
- Equity Issuance: The Company issued 2,926,166 new unregistered warrants (New Warrants) and 87,785 advisor warrants.
- Registration Obligations: The Company must file a resale registration statement for the New Warrant Shares within 45 calendar days of the agreement date.
- Advisor Rights: Wallach Beth Capital, LLC received a right of first refusal for six months on future equity/debt offerings and a contingent fee structure for future introductions within 12 months.
Guidance, Risks, and Unusual Items
- Stockholder Approval Requirement: The New Warrants are not exercisable until the Company receives stockholder approval of their exercisability and the issuance of shares upon exercise.
- Cashless Exercise Provision: If a registration statement is not effective after six months (or the stockholder approval date, whichever is later), holders may elect a cashless exercise.
- Fundamental Transaction Rights: In the event of a Fundamental Transaction, holders have the right to require the Company to redeem unexercised warrants for cash based on the Black Scholes Value, subject to specific conditions regarding transactions not in the Company's control.
- Ownership Caps: Holders cannot exercise if it would result in beneficial ownership exceeding 4.99% (or 9.99% upon election) of outstanding shares.
- Unusual Item: The transaction structure involves a "warrant inducement" where the Company pays a premium (via new warrants) to induce immediate cash exercise of existing warrants to raise capital.
Investor Verification Checklist
- Verify the exact number of shares issued upon exercise and the final net proceeds after deducting the 8% advisor fee and expenses.
- Confirm the timeline for the filing and effectiveness of the resale registration statement (Form S-1) for the New Warrant Shares.
- Monitor the schedule for the required stockholder vote to approve the exercisability of the New Warrants.
- Review the impact of the 2,926,166 new warrants and 87,785 advisor warrants on the Company's fully diluted share count.
- Assess the Company's current cash position relative to the $1.4 million raised to determine runway extension.